Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment (ILI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01920516
Recruitment Status : Unknown
Verified February 2019 by Giammaria Fiorentini, International Group of Endovascular Oncology.
Recruitment status was:  Recruiting
First Posted : August 12, 2013
Last Update Posted : February 27, 2019
Information provided by (Responsible Party):
Giammaria Fiorentini, International Group of Endovascular Oncology

Brief Summary:

In-transit metastases occur in approximately 3% of melanoma patients, can be very symptomatic and the survival in this group may be prolonged. In-transit melanoma metastases are often confined to a limb. In this circumstance, treatment by isolated limb perfusion or isolated limb infusion can be a remarkably effective regional treatment option. Isolated limb infusion (ILI) was introduced in 1992 and is a technique used to deliver regional chemotherapy to treat advanced melanoma confined to a limb. Regional chemotherapy with melphalan delivered by isolated limb perfusion (ILP) or ILI are effective treatment options for in-transit melanoma and are generally well tolerated.

ILI is a less invasive and simpler alternative to ILP. Complete response rates are 45- 69% for ILP and 23-44% for ILI. The limb is often warmed to lower temperatures in ILI compared to ILP and the limb becomes progressively more hypoxic and acidotic during ILI, each of these parameters potentially having an effect on outcome. ILP & ILI are used primarily as palliative options when excision of in-transit metastases is unfeasible but can be used as an adjunctive procedure to surgery, for other tumour types such as merkel cell carcinoma, and can be repeated if indicated. For ILI correction of melphalan dose for ideal body weight has been shown to substantially decrease the rates of severe local toxicity while maintaining complete response rates, but overall response rate is reduced.

Response to ILI, moreover, is different in upper and lower limbs. ILI for Upper limbs disease is associated with similar complete response rates but lower toxicity than ILI for Lower limbs E disease and with different physiologic sequelae despite comparable methods. The Upper limbs appears relatively resistant to toxic effects of melphalan-based ILI as currently performed, which suggests a potential for further optimization of drug dosing for Upper limbs ILI.

Regional therapy is an excellent therapeutic modality for disease limited to a limb and furthermore serves as an excellent model for scientific investigation, both clinical and translational. In this study we want to collect data on isolated limb infusion of chemotherapy to monitor efficacy and tolerability in patients with melanoma metastases of the arm or leg that cannot be removed by surgery.

Condition or disease Intervention/treatment
Metastatic Melanoma Drug: Melphalan

Show Show detailed description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Observational Study on Isolated Limb Perfusion of Melphalan in Treating Patients With Metastasis or Recidivism of Limb Melanoma or Sarcoma That Are Not Operable
Study Start Date : July 2013
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : July 2020

Group/Cohort Intervention/treatment

Day +1:

Intra femoral infusion of Melphalan at the dosage 1mg/ Kg

Intra femoral infusion of Melphalan Second ILI treatment can be repeated at side effects recovery ( following oncologist ' s planning of cure).

Day +30: The above procedure is repeated.

Day +90: In case of response, a third administration following the above procedures will be repeated.

Drug: Melphalan
Melphalan 1mg/kgr is rapidly infused into the isolated limb via the arterial catheter after the inflation of venous baloon catheter.
Other Name: Alkeran

Primary Outcome Measures :
  1. Tumor response [ Time Frame: 12 months ]

    Response must be assessed by repeating the following examinations, at Day 30, Day 90 and Day 120 after start of treatment:

    Chest-abdomen CAT scan with and without contrast medium (refer to Section 4). Evaluation will be based on RECIST criteria [18-22 ] cancer markers (CEA, CA 19.9)

Secondary Outcome Measures :
  1. survival rate [ Time Frame: 12 months ]
    percentage of patients alive

  2. time to progression [ Time Frame: 12 months ]
    time from treatment start to progression

  3. number of adverse events [ Time Frame: 4 months ]
    number of adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
primary care clinic

Inclusion Criteria:

  1. Histologically proven primary or recurrent, regional melanoma or soft tissue sarcoma that is not amenable to surgical resection
  2. Majority (greater than 95%) of disease must be distal to the apex of the femoral triangle in the lower limb and the deltoid insertion in the upper limb
  3. Bidimensionally measurable disease in the extremity
  4. Patients with disease beyond the limb are eligible if their extremity disease requires palliative treatment in the judgment of their physician
  5. Age: more than 18
  6. Karnofsky 70-100%
  7. Life expectancy: At least 6 months
  8. Hematopoietic: WBC at least 3,000/mm^3
  9. Renal: Creatinine less than 2.0 mg/dL
  10. At least 4 weeks since prior antitumor therapy and recovered
  11. At least 2 weeks since prior antibiotics

Exclusion Criteria:

  1. Signs or symptoms of vascular insufficiency (no history of claudication or other ischemic peripheral vascular disease)
  2. pregnant or nursing
  3. other concurrent serious illness
  4. severe diabetes
  5. prior extremity complications due to diabetes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01920516

Layout table for location contacts
Contact: Donatella Sarti, PhD +39072136 ext 4018

Layout table for location information
Azienda Ospedaliera Ospedali Riuniti Marche Nord, Presidio Ospedaliero San Salvatore Recruiting
Pesaro, PU, Italy, 61122
Contact: Giammaria Fiorentini, MD    +39072136 ext 4124   
Principal Investigator: Giammaria Fiorentini, MD         
Sponsors and Collaborators
International Group of Endovascular Oncology
Layout table for investigator information
Principal Investigator: Giammaria Fiorentini, MD International Group of Endovascular Oncology
Additional Information:
Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Giammaria Fiorentini, Dr., International Group of Endovascular Oncology Identifier: NCT01920516    
Other Study ID Numbers: ILI01
ILI100513 ( Other Identifier: IGEVO )
First Posted: August 12, 2013    Key Record Dates
Last Update Posted: February 27, 2019
Last Verified: February 2019
Keywords provided by Giammaria Fiorentini, International Group of Endovascular Oncology:
Isolated limb infusion
Limb Melanoma
Tumor response
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplasms, Connective and Soft Tissue
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs